This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tubafard, S Articles by Fatemi, S. Search for Related Content PubMed PubMed Citation Articles by Tubafard, S Articles by Fatemi, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB BISMUTH, ELEMENTAL DESFERRIOXAMINE IRON Social Bookmarking                         What's this?

Chelation of bismuth by combining desferrioxamine and deferiprone in rats

Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, Iran

SJ Fatemi

Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, Iran fatemijam{at}yahoo.com

Consumption and production of bismuth compounds are increasing, however, a little information on the toxic effect and also the effective method in removal of bismuth compounds are available. The present research aimed to characterize the potential efficiency of two chelators after bismuth administration for 55 days following two dose levels of 20 and 40 mg/kg body weight daily to male rats. However, we found abnormalities after bismuth administration in clinical signs, such as body weight, kidneys and liver damages, a black line on gums and skin reactions. Furthermore, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing bismuth from the body was considered. Along this line, two known chelators deferiprone (1, 2-dimethy1-3-hydroxypyride-4-one, L₁) and desferrioxamine (DFO) were chosen and tested in the acute rat model. Chelators were given orally (L₁) or intraperitoneally (DFO) as a single or combined therapy for the period of a week. Doses of L₁ and DFO were 110 mg/kg body weight in experiments. Bismuth and iron concentrations in various tissues were determined by graphite furnace and flame atomic absorption spectrometry, respectively. The combined chelation therapy results show that DFO and L₁ are able to remove bismuth ions from the body, whereas iron concentration returned to the normal level and symptoms are also decreased. DFO was more effective than L1 in reducing bismuth concentration in tissues. The efficiency of DFO + L₁ is more than DFO or L₁ in removing bismuth from organs. Our results are indicative that the design procedure might be useful for preliminary in-vivo testing of the efficiency of chelating agents. Results of combined chelators’ treatment should be confirmed in a different experimental model before extrapolation to other systems. This testing procedure of course does not provide all the relevant answers for efficiency of chelating agents in bismuth toxicity.

Key Words: bismuth • bismuth chelators • bismuth rats • chelation • deferiprone • desferrioxamine • iron

Toxicology and Industrial Health, Vol. 24, No. 4, 235-240 (2008)
DOI: 10.1177/0748233708095771


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?